AngioDynamics, Inc. (ANGO)
NASDAQ: ANGO · Real-Time Price · USD
9.86
-0.19 (-1.89%)
At close: Jan 9, 2026, 4:00 PM EST
9.91
+0.05 (0.51%)
After-hours: Jan 9, 2026, 7:35 PM EST
AngioDynamics Revenue
AngioDynamics had revenue of $79.43M in the quarter ending November 30, 2025, with 9.04% growth. This brings the company's revenue in the last twelve months to $307.31M, up 7.26% year-over-year. In the fiscal year ending May 31, 2025, AngioDynamics had annual revenue of $292.50M, down -3.76%.
Revenue (ttm)
$307.31M
Revenue Growth
+7.26%
P/S Ratio
1.32
Revenue / Employee
$455,268
Employees
675
Market Cap
406.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| May 31, 2025 | 292.50M | -11.42M | -3.76% |
| May 31, 2024 | 303.91M | -34.84M | -10.28% |
| May 31, 2023 | 338.75M | 22.53M | 7.13% |
| May 31, 2022 | 316.22M | 25.21M | 8.66% |
| May 31, 2021 | 291.01M | 26.85M | 10.17% |
| May 31, 2020 | 264.16M | -6.48M | -2.39% |
| May 31, 2019 | 270.63M | 8.98M | 3.43% |
| May 31, 2018 | 261.66M | -8.13M | -3.01% |
| May 31, 2017 | 269.79M | -84.10M | -23.77% |
| May 31, 2016 | 353.89M | -2.64M | -0.74% |
| May 31, 2015 | 356.53M | 2.11M | 0.60% |
| May 31, 2014 | 354.43M | 12.51M | 3.66% |
| May 31, 2013 | 341.92M | 120.00M | 54.07% |
| May 31, 2012 | 221.92M | 6.17M | 2.86% |
| May 31, 2011 | 215.75M | -285.00K | -0.13% |
| May 31, 2010 | 216.04M | 20.98M | 10.76% |
| May 31, 2009 | 195.05M | 28.55M | 17.15% |
| May 31, 2008 | 166.50M | 54.27M | 48.36% |
| Jun 2, 2007 | 112.23M | 33.78M | 43.05% |
| Jun 3, 2006 | 78.45M | 18.16M | 30.12% |
| May 28, 2005 | 60.29M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ANGO News
- 3 days ago - AngioDynamics, Inc. (ANGO) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 3 days ago - AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability - Business Wire
- 10 days ago - AngioDynamics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga
- 11 days ago - AngioDynamics: Growth Remains Under The Radar - Seeking Alpha
- 17 days ago - AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026 - Business Wire
- 18 days ago - AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - AngioDynamics, Inc. (ANGO) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 2 months ago - AngioDynamics to Participate in the UBS Global Healthcare Conference - Business Wire